Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
Background: Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative expe...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
November 2017
|
| In: |
European journal of cancer
Year: 2017, Volume: 86, Pages: 233-239 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2017.09.016 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/j.ejca.2017.09.016 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804917312972 
|
| Author Notes: | S.K. Metzelder, T. Schroeder, M. Lübbert, M. Ditschkowski, K. Götze, S. Scholl, R.G. Meyer, P. Dreger, N. Basara, M.F. Fey, H.R. Salih, A. Finck, T. Pabst, A. Giagounidis, G. Kobbe, E. Wollmer, J. Finke, A. Neubauer, A. Burchert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1582363390 | ||
| 003 | DE-627 | ||
| 005 | 20250206100341.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181029s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2017.09.016 |2 doi | |
| 035 | |a (DE-627)1582363390 | ||
| 035 | |a (DE-576)512363390 | ||
| 035 | |a (DE-599)BSZ512363390 | ||
| 035 | |a (OCoLC)1341021891 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Metzelder, Stephan |d 1977- |e VerfasserIn |0 (DE-588)130383813 |0 (DE-627)500677271 |0 (DE-576)298162504 |4 aut | |
| 245 | 1 | 0 | |a Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation |c S.K. Metzelder, T. Schroeder, M. Lübbert, M. Ditschkowski, K. Götze, S. Scholl, R.G. Meyer, P. Dreger, N. Basara, M.F. Fey, H.R. Salih, A. Finck, T. Pabst, A. Giagounidis, G. Kobbe, E. Wollmer, J. Finke, A. Neubauer, A. Burchert |
| 264 | 1 | |c November 2017 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.10.2018 | ||
| 520 | |a Background: Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available. Methods: We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD-positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy. Findings: With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years. Interpretation: Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT. | ||
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a FLT3-ITD | |
| 650 | 4 | |a Hematopoietic stem cell transplantation | |
| 650 | 4 | |a Sorafenib | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 86(2017), Seite 233-239 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation |
| 773 | 1 | 8 | |g volume:86 |g year:2017 |g pages:233-239 |g extent:7 |a Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2017.09.016 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804917312972 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181029 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 999 | |a KXP-PPN1582363390 |e 3029938638 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation","title":"Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation"}],"person":[{"family":"Metzelder","display":"Metzelder, Stephan","given":"Stephan","role":"aut"},{"family":"Dreger","display":"Dreger, Peter","role":"aut","given":"Peter"}],"name":{"displayForm":["S.K. Metzelder, T. Schroeder, M. Lübbert, M. Ditschkowski, K. Götze, S. Scholl, R.G. Meyer, P. Dreger, N. Basara, M.F. Fey, H.R. Salih, A. Finck, T. Pabst, A. Giagounidis, G. Kobbe, E. Wollmer, J. Finke, A. Neubauer, A. Burchert"]},"note":["Gesehen am 29.10.2018"],"relHost":[{"pubHistory":["28.1992 -"],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"part":{"text":"86(2017), Seite 233-239","year":"2017","volume":"86","pages":"233-239","extent":"7"},"language":["eng"],"id":{"eki":["266883400"],"issn":["1879-0852"],"zdb":["1468190-0"]},"disp":"Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantationEuropean journal of cancer","corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"origin":[{"dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisher":"Elsevier ; Pergamon Press","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}],"recId":"266883400","titleAlt":[{"title":"EJC online"}],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"id":{"doi":["10.1016/j.ejca.2017.09.016"],"eki":["1582363390"]},"physDesc":[{"extent":"7 S."}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"November 2017"}],"recId":"1582363390","type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a METZELDERSLONGTERMSU2017 | ||